These findings collectively highlight the critical role of ATXN2 in ALS and the potential of targeting it for therapeutic interventions, as demonstrated by the beneficial effects of antisense oligonucleotide technology in preclinical models (2, 5). This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.